Relative Bioavailability of Three Different BI 456906 Formulations Following Subcutaneous Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Trial)
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Survodutide (Primary)
- Indications Liver cirrhosis; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 12 Jun 2025 Status changed from active, no longer recruiting to completed.
- 13 May 2025 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2025 Status changed from not yet recruiting to recruiting.